Evidence map›Paper›PMID 38301040›Full record

ArticleAging2024

MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.

Jin Tao, Jinshan Cui, Yu Xu, Yafeng Fan, Guodong Hong, Qiaoxia Zhou, Guoqiang Wang, Leo Li, Yusheng Han, Chunwei Xu and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jin TaoDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jinshan CuiDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yu XuBurning Rock Biotech, Guangzhou, Guangdong, China.
Yafeng FanDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Guodong HongDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qiaoxia ZhouBurning Rock Biotech, Guangzhou, Guangdong, China.
Guoqiang WangBurning Rock Biotech, Guangzhou, Guangdong, China.
Leo LiBurning Rock Biotech, Guangzhou, Guangdong, China.
Yusheng HanBurning Rock Biotech, Guangzhou, Guangdong, China.
Chunwei XuInstitute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Wenxian WangDepartment of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Shangli CaiBurning Rock Biotech, Guangzhou, Guangdong, China.
Xuepei ZhangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Burning Rock Biotech (China) · CNFirst Affiliated Hospital of Zhengzhou University · CNChinese Academy of Sciences · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsDNA-Binding ProteinsHumansImmunotherapyMaleMTOR InhibitorsPhosphatidylinositol 3-KinasesPrognosisTranscription FactorsTumor MicroenvironmentDNA-Binding ProteinsMAEL protein, humanMTOR InhibitorsPhosphatidylinositol 3-KinasesTranscription Factorsclear cell renal cell carcinomaimmunotherapyMAELpan-cancer analysisprognosis

Identifiers

PMID38301040
PMCPMC10911358
OpenAlexW4391384232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.